ABVX
Abivax
Stock NASDAQ – Stock Market Prices, News & Analysis
Abivax develops pharmaceutical treatments for inflammatory, viral, and immuno-oncological diseases.
Abivax
ABVX
Abivax develops pharmaceutical treatments for inflammatory, viral, and immuno-oncological diseases.
Price history of Abivax
Price history of Abivax
Performance & Momentum
Abivax Soars 1700% in 2025 on Strong Clinical Results
Abivax, listed on NASDAQ under the ticker ABVX, delivered an outstanding 1742% gain in 2025, driven by positive clinical data and renewed analyst confidence. Its inclusion in the Nasdaq Biotechnology Index boosted the stock's appeal. Brokerages like Piper Sandler and Guggenheim have raised their price targets, expecting significant upside potential around the obefazimod treatment. While this momentum creates a favorable environment for investors, caution is advised due to biotech sector volatility.
Strategic Analysis
Abivax • 2026
Abivax is a research biopharmaceutical company focused on developing innovative treatments in inflammatory, viral and immuno-oncology diseases. Its positioning is built on strong scientific intensity and value creation through high-potential clinical programs, typical of niche players capable of delivering a significant rerating in the event of success.
- Targeted expertise in indications with high unmet medical need, offering significant valuation upside in the event of positive clinical results
- Niche positioning in French biopharma, combining therapeutic research with differentiated innovation potential
- Very strong long-term stock market performance, reflecting the market's ability to price in substantial value creation potential
- High dependence on clinical and regulatory milestones, with the binary risk inherent to the sector
- Limited economic visibility until the treatments progress through development and commercialization stages
Momentum appears very strong and reflects sustained market interest in the story, likely driven by a favorable view of the clinical potential and the optionality embedded in the pipeline. For retail investors, this signals constructive share-price dynamics, but also a valuation that is highly sensitive to development announcements, which underscores the need to closely monitor scientific and regulatory catalysts.
Similar stocks to Abivax
Recent News
Abivax
Abivax Unveils 22 Obefazimod Studies; Strong Q3 2025
4 months agoAbivax announces acceptance of 22 abstracts evaluating obefazimod for chronic inflammatory bowel diseases, including an oral presentation on preclinical anti-fibrotic results at the ECCO 2026 congress. Additionally, the company reported Q3 2025 results, showing a cash position of €589.7 million, providing financial visibility through Q4 2027. These scientific advances strengthen Abivax's position in the rapidly growing innovative ulcerative colitis treatment market, likely boosting investor interest.
Abivax Shares Jump 57% in 90 Days on Strong Outlook
5 months agoAbivax's stock surged 57% over the past three months, driven by renewed investor interest and impressive annual revenue growth. This momentum is further supported by Zacks' recent buy rating highlighting the company's promising earnings prospects. These positive factors, alongside a booming biotech sector, could sustain Abivax's stock performance in the near term.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
